-
Shenzhen United Family Hospital Partners with GBA Medical Delegation
•
Shenzhen United Family Hospital has struck a partnership with a medical delegation from the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), aimed at accelerating high-quality healthcare development and medical exchanges in the region. This collaboration is a significant step towards enhancing the healthcare ecosystem in the GBA. Shenzhen United Family Hospital:…
-
Vincentage Raises RMB 100 Million for Innovative Drug Development
•
Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6 million) in its latest financing round. This significant funding will be used to accelerate clinical studies and regulatory filings for multiple innovative drugs, particularly oral small molecule GLP-1RA drugs, as well as to develop new…
-
Sequanta and Grandomics Collaborate on Ultra-High Throughput Sequencing Lab
•
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences Co., Ltd, a Beijing-based biotech specializing in applying bioinformatics, genomics, and cutting-edge internet technologies to clinical medicine and personal health, have signed a long-term collaboration agreement. The partnership aims to integrate short-read sequencing and long-read…
-
Luzhu Biotech Files for IPO in Hong Kong, Sponsored by CICC
•
Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made another initial public offering (IPO) filing with the Hong Kong Stock Exchange, sponsored by CICC. This marks the company’s second attempt at going public on the bourse, following the failure of its first IPO attempt…
-
Mindray Launches First Wireless Handheld Ultrasound System, TE Air
•
China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s first wireless handheld ultrasound system, branded TE Air. This innovative device represents a historic breakthrough in image quality, integrating professional-level imaging into a compact and lightweight wireless system for ease of use in various medical…
-
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
•
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This…
-
Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment in a Phase I clinical study for its tetravalent influenza virus split vaccine. This marks a significant step in the development of a vaccine designed to provide broader protection against influenza, particularly for individuals aged…
-
Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610
•
China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of subject enrollment in a clinical study for its novel adjuvanted recombinant shingles vaccine, REC610. This milestone marks a significant step in the development of a vaccine designed to provide enhanced protection against shingles, particularly for…
-
Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine
•
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and first subject enrollment in a Phase I clinical study for its 20-valent pneumonia vaccine. This marks a significant step in the development of a vaccine designed to provide broader protection against pneumonia. Vaccine Development and…
-
Gracell Biotechnologies Gains IND Approval for GC012F in China
•
Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) for its chimeric antigen receptor (CAR) T cell candidate GC012F. The dual BCMA/CD19-targeted therapy is set to be assessed in treating relapsed/refractory multiple myeloma (r/r MM), marking a significant step in the development…
-
ThinmedTech Partners with West China Hospital for CKD Digital Therapy
•
ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership with West China Hospital. The collaboration aims to work together on medical research and product transformation in the area of “chronic kidney disease (CKD) sodium restriction digital therapy.” This partnership marks a significant step in…
-
RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study
•
China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products Administration (NMPA) to initiate an open, single-center Phase Ib/II clinical study. The study will assess the safety, efficacy, and pharmacokinetics of its antibody-drug conjugate (ADC) candidate RC48 (disitamab vedotin) combined with Hengrui pharmamceuticals’ pyrotinib, a…
-
Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) in Zhejiang. This recombinant protein vaccine is recommended by the national second dosage (fourth shot) booster immunization plan and is suitable for use in the elderly, immune-compromised individuals, and populations with complications.…
-
Hengrui Pharmaceuticals Licenses SHR2554 to Treeline Biosciences
•
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced a licensing agreement with US-based Treeline Biosciences, Inc. The deal grants Treeline exclusive development, manufacturing, and commercialization rights to the pipeline candidate SHR2554 in markets outside of the Greater China area. This strategic partnership aims to expand the global reach of SHR2554,…
-
CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus Pharmaceuticals Inc. The deal pertains to CSPC’s anti-nectin-4 antibody drug conjugate (ADC) SYS6002. Under the terms of the agreement, Corbus obtains development and commercialization rights to SYS6002 in the United States, EU, United Kingdom, Canada,…
-
Mingche Biotechnology Secures Pre-Series A Funding for Medical Device Innovation
•
China-based high-value medical device firm Mingche Biotechnology (Suzhou) Co., Ltd has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. This significant capital raise was led by Suzhou Industrial Park Development Zhidao Equity Investment Partnership and Qianrong Capital, with additional contributions from Haida Investment. The funds…
-
Dessight Biomedical Secures Pre-Series A Funding for Ophthalmic Innovations
•
Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. This significant capital injection was led by Linear Venture, with GL Ventures also participating. The funds will be directed towards market filing for an ophthalmic surgery robot, the development of microsurgery robots, and…
-
Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody
•
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase I clinical study for its BA1106, an in-house developed CD25 monoclonal antibody (mAb). The study, filed by subsidiary Shandong BoAn Biotechnology Co., Ltd, is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of…
-
Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for its ZGGS15, a bispecific antibody (BsAb) targeting LAG-3 and TIGIT in advanced solid tumors, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone as ZGGS15 is touted…
-
Kintor’s GT20029 Shows Positive Results in US Phase I Study for AGA and Acne
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I clinical study in the United States for its GT20029, a treatment for androgenetic alopecia (AGA) and acne. This marks a significant step in the development of a novel treatment option for these common conditions. Phase…
